로딩 중…
StockDiggingStockDigging

Bio-Techne Corporation

TECH· NASDAQ
$57.95+5.36%
2026-06-18

Price Chart

Bio-Techne Corporation+16.08%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$9.07B
Revenue$1.21B
Net Income$110M
Total Assets$2.55B
Net Assets$2.09B
Employees3,100
Value
P/E82.80x
P/B4.35x
PEG0.66x
P/S7.49x
EV/EBITDA35.34x
FCF Yield2.97%
Profitability
ROE5.25%
ROA4.30%
Op. Margin12.70%
Revenue Growth-1.51%
Earnings Growth126.04%
Financial Health
Debt Ratio22.31%
Total Debt$290M
FCF$270M
Cash$210M
Current Ratio4.49x
Net Debt/EBITDA0.31x
Dividend
Div. Yield0.55%
Div. Growth0.06%
Performance
1Y Return16.08%
1M Return27.45%
From 52W High-19.58%
1Y MDD-39.26%
Trading
Volume2,341,321 shares
Trading Value$134M
Per Share
EPS$0.52
BPS$12.90

Company Info

CEO Mr. Kim Kelderman
Employees 3,100
HQ Minneapolis, United States

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.